Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...

The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first monobactam/β-lactamase inhibitor combination to be cleared in the US for ...

Emblaveo is a combination of aztreonam, a monobactam antibiotic, and avibactam, a beta-lactamase inhibitor that can restore the ability of aztreonam to fight the types of bacteria than can become ...

The approval marks the therapy as the first and only intravenous fixed-dose monobactam/β-lactamase inhibitor combo antibiotic. Emblaveo targets cIAI caused by Gram-negative microorganisms, including ...

Emblaveo (aztreonam and avibactam) is a fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. The combination drug can be used in Gram-negative bacterial infections ...

The approval is based limited clinical safety and efficacy data for Emblaveo. It combines aztreonam, a monobactam β-lactam, with avibactam, a broad-spectrum β-lactamase inhibitor. The approval was ...

8 February 2025 Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International Region at Gilead and Kite Oncology. Mr Santoro outlines the ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...

Drugmaker AbbVie announced late last week that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam-avibactam) for treating complicated intra-abdominal infections (cIAIs). The ...

This marks the first fixed-dose, intravenous monobactam/ Beta -lactamase inhibitor combination antibiotic. In combination with metronidazole, Emblaveo is approved for patients aged 18 and older ...